Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05489679
NCT05489679TerminatedPhase 1

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Accutar Biotechnology Inc3 sites in 1 country6 target enrollmentStarted: October 1, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Terminated
Enrollment
6
Locations
3
Primary Endpoint
Incidence of treatment emergent adverse events(TEAEs) from AC682 monotherapy
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This clinical trial is evaluating AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to:

  1. To evaluate the safety and tolerability of AC682
  2. To evaluate the pharmacokinetic of AC682
  3. To evaluate the preliminary anti-tumor activity of AC682

Detailed Description

This is a Phase I, open-label dose-escalation study of AC682, an orally available estrogen receptor degrader, given as a single agent.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients must be ≥18 years-of-age at the time of signing of the ICF
  • •Histologically and/or cytologically confirmed advanced estrogen receptor positive (ER+) human epidermal growth factor 2 negative (HER2-) breast cancer
  • •Female patients must be postmenopausal
  • •At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 or at least 1 predominantly lytic bone lesion in the absence of measurable disease
  • •Previously received at least 1 endocrine therapy regimen; concomitant use of cyclin-dependent kinase (CDK) 4/6 inhibitor(s) is acceptable; Previous chemotherapy is not required, but up to 2 prior regimens of cytotoxic chemotherapy is allowed.
  • •Patients who have adequate organ functions at baseline

Exclusion Criteria

  • •Treatment with any of the following:
  • •systemic anti-cancer chemotherapy, biologic, or hormonal agent from a previous treatment regimen or clinical study within 4 weeks prior to the first dose of AC682; systemic small molecules from a previous treatment regimen or clinical study within 14 days or 5 half-lives (whichever is longer) prior to the first dose of AC682 (at least 10 days must have elapsed between the last dose of such agent and the first dose of study drug)
  • •Received radiotherapy (including radioactive isotope therapy) within 4 weeks prior to the first dose of AC682
  • •Major surgery (excluding placement of vascular access) within 4 weeks of first dose of AC682
  • •With known metastasis to the brain
  • •Any condition that impairs a patient's ability to swallow whole pills. Impairment of gastrointestinal function (GI) or GI disease or other condition at baseline that will interfere significantly with the absorption, distribution, or metabolism of AC
  • •Use of prophylactic growth factors and blood transfusions ≤14 days prior to the first dose of AC682 and during dose limiting toxicity observation period

Arms & Interventions

AC682

Experimental

This arm will evaluate AC682 monotherapy administered in 28-day cycles. The participants will participate in this dose escalation arm.

Intervention: AC682 (Drug)

Outcomes

Primary Outcomes

Incidence of treatment emergent adverse events(TEAEs) from AC682 monotherapy

Time Frame: Throughout the study completion, approximately 24 months

Number of adverse events as characterized by type, frequency, seriousness, and relationship to AC682

Incidence of dose limiting toxicities (DLTs) from AC682 monotherapy

Time Frame: 28 days

Number of subjects with DLT

Secondary Outcomes

  • To evaluate the preliminary anti-tumor activity of AC682:(Throughout the study completion, approximately 24 months)
  • To determine the PK of AC682 after a single dose or multiple doses:(At predefined intervals throughout the study completion, approximately 24 months.)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials

Terminated
Phase 1
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast CancerBreast Cancer
NCT05080842Accutar Biotechnology Inc21
Active, not recruiting
Phase 1
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast CancerBreast Cancer
NCT05654532Accutar Biotechnology Inc100
Terminated
Phase 2
Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine TherapyCancer of the BreastNeoplasms, BreastBreast Cancer
NCT00661531Georgetown University11
Terminated
Phase 1
VNRX-9945 Safety and Pharmacokinetics in Healthy Adult VolunteersHealthy Volunteers
NCT04845321Venatorx Pharmaceuticals, Inc.32
Completed
Not Applicable
A study to detect the effect of radiofrequent ablation in combination with ipilimumab in patients with eye melanoma that spread out to the liver.uveal melanomaliver metastasesoog melanoomlever metastasen
NL-OMON26122KI-AV44
A Study of AC682 In Chinese Patients With... | Clinical Trial